New Treatment Options For Alopecia Areata

Alopecia areata, affecting 2% of the population, is a common autoimmune disorder that significantly impacts quality of life, often leading to depression and unemployment. This review discusses the primary manifestations and pathogenesis of alopecia areata, with a focus on current treatment options and their effectiveness. Notably, the JAK inhibitor Baricitinib, recently approved for advanced alopecia areata, demonstrates unprecedented efficacy but has sparked debate over the costs and risks associated with treating what is considered a cosmetic condition.